Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 06/14/24 03:15:00 on US and Canada Markets.
2024-06-14 03:15:00 ET The biggest investment mistakes you make are likely to come from situations where you don't fully understand the asset you are buying. That's actually easy to do in the exchange-traded fund (ETF) space, because the logic behind many of the ETFs out there is complex an...
2024-06-14 03:12:00 ET Warren Buffett's investment decisions in recent quarters have garnered little positive excitement. His team at Berkshire Hathaway sold more stock than it has bought in the first quarter of 2024, and the growing pile of cash could leave investors wondering whether ...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire - Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , inc...
2024-06-14 03:05:00 ET There's no getting around the impact of artificial intelligence (AI) in tech circles since early last year, and Broadcom (NASDAQ: AVGO) is a key player in the space. The company's semiconductors and data center infrastructure play a critical part in the AI...
2024-06-14 03:03:00 ET There are plenty of reasons to be pessimistic about the electric vehicle (EV) industry now, but that could also make it a perfect time to buy in while stock prices are depressed. To be fair, not every EV investment is going to pan out as many companies are in a cash c...
- Results from CLIMB-111, -121 and -131 accepted for oral presentation - - Data from these trials, with the longest follow-up of more than five years, demonstrate transformative, consistent and durable benefit of CASGEVY™ - - Safety profile consistent with busulfan condit...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (e...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic ...
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide in the open-label extension of the REVIV...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.72%Change Percent:
WesBanco Inc. Company Name:
WSBC Stock Symbol:
NASDAQ Market:
wesbanco.com Website: